[Corrections] Correction to Lancet Oncol 2017; 18: 556–57

Kotsakis A, Georgoulias V. Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types. Lancet Oncol 2017; 18: 556–57—In this Comment, the term 'immune-related' should have read 'infusion-related' in two phrases. The two affected sentences should have read as follows: "However, an important finding from these two studies was that the frequency of infusion-related reactions exceeded 20%; infusion-related reactions are uncommon with the other approved immunotherapeutic agents, with an estimated frequency of about 1–2%" and "Once again, ongoing phase 3 trials (NCT02395172, NCT02576574) might shed light on the frequency, significance, and severity of infusion-related adverse events and how best to manage them." These corrections have been made to the online version as of July 26, 2017.

http://ift.tt/2tDVkU5